Noticias y eventos de Champions Oncology Inc (CSBR)CSBRChampions Oncology Inc

Tech Stocks Plunge, S&P 500 Falls for Fourth Consecutive Day

Major indices were down sharply for the fourth consecutive session, though in contrast to the selling earlier in the week, tech-heavy indices - S&P 500 and Nasdaq Composite - were hit harder than Dow Industrials.  Technology, along with Basic Materials, were the worst-performing sectors in the S&P 500 as AI buildout-positive areas of the market buckled under the ongoing strain in borrowing costs.  Semiconductors, Hardware, and Memory stocks were down across the board as the yield on the 10-year Treasury note reached new multi-year highs, jumping another 11 basis points to 4.94%.  Even the Energy sector was weighed down by the more ominous overall market sentiment in spite of yet another spike in oil prices amid continued escalation in the Middle East - WTI Crude Oil was up 7% on Thursday and has picked up another 2% in the evening hours, rising above $104 per barrel.  In the opening hours of the evening session, index futures are little changed, with S&P e-minis flat and the Nasdaq 100 contract down by a decimal.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Frequency Electronicsup 28.3%Copartup 8.4%RHup 6.5%Oracleup 4.2%ALSO HIGHER -ACV Auctionsup 43.8% after being acquired by CopartDOWN AFTER EARNINGS -Zumiezdown 16.7%Champions Oncologydown 2.9%Adobedown 2.0%IBEX Limiteddown 2.0%ALSO LOWER -CPI Card Groupdown 14.0% after selling stock for holders

Champions Reports Q1 Revenue of $15.2M

Reports Q1 revenue $15.2M vs. $14M last year. Robert Brainin, CEO of Champions, commented, "We delivered strong performance in the first quarter of fiscal 2027, with improved study execution and conversion in our core research services business driving higher revenue and materially better margins. We are also seeing increased commercial activity around our data offerings as we work to broaden that business across a larger customer base."

Champions Oncology Expands Radiopharmaceutical Development Platform

Champions Oncology announced the expansion of its integrated radiopharmaceutical development platform with new in-house SPECT/CT imaging capabilities. This capability extends Champions' existing radiopharmaceutical services across radiolabeling, biodistribution, efficacy and clinically relevant oncology models. Researchers can now longitudinally visualize and quantify radiopharmaceutical uptake in vivo, and connect those findings with terminal biodistribution, therapeutic response and the molecular characteristics of the tumor model.